, a respected clinical-stage biopharmaceutical company centered on the treating dementia, today announced the acceptance of two presentations at the Alzheimer's Association International Meeting 2015 getting held in Washington, D.C. From 18-23 July, 2015. The info will be provided via oral and poster presentations the following: Efficacy of RVT-101 in Mild-Moderate Alzheimer's Disease: Completer Evaluation : The Efficacy of RVT-101, a 5-HT6 Receptor Antagonist, While an Adjunct to Donepezil in Adults with Mild-to-Average Alzheimer's Disease: Completer Evaluation of a Phase 2b Study can be presented through the Developing Topics Program: Clinical Trial Outcomes on Wednesday, 22 July, 2015, 2:00-3:30 p.m.IL-21 protein, a cytokine currently being tested in an open-label, Phase II clinical study as a potential immunotherapy treatment for metastatic melanoma. An earlier-stage pipeline of six biologic medication candidates, including an anti-IL-31 antibody, in pre-clinical development for atopic dermatitis currently. Potential royalty and milestone obligations from six partnered applications in a variety of stages of clinical advancement by EMD Serono, Inc., an affiliate marketer of Merck KGaA, and Novo Nordisk.